| Literature DB >> 28572674 |
Hiroki Kaneko1, Kei Takayama2, Tetsu Asami2,3, Yasuki Ito2, Taichi Tsunekawa2, Takeshi Iwase2, Yasuhito Funahashi4, Shinji Ueno2, Norie Nonobe2, Shunsuke Yasuda2, Ayana Suzumura2, Hideyuki Shimizu2, Reona Kimoto2, Shiang-Jyi Hwang2,5, Hiroko Terasaki2.
Abstract
Silicone oil (SO) is an intraocular surgical adjuvant that reduces the surgical complications in refractory retinal diseases, although membrane and cellular proliferation is often seen even in SO-filled eyes. We hypothesised that the fluid in the space between the SO and the retina, named the "sub-silicone oil fluid (SOF)", enhances these biological responses. We proposed a safe method for SOF extraction. We also analysed inflammatory cytokine expressions and SOF osmotic pressures from eyes with rhegmatogenous retinal detachment (RRD), proliferative diabetic retinopathy (PDR), proliferative vitreoretinopathy (PVR) and macular hole-associated retinal detachment (MHRD). Interleukin (IL)-10, IL-12p40, IL-6, monocyte chemotactic protein-1, and vascular endothelial growth factor (VEGF) in the SOF with PVR were significantly higher than in those with RRD or MHRD. Fibroblast growth factor-2, IL-10, IL-12p40, IL-8, VEGF, and transforming growth factor beta 1 levels in eyes with exacerbated PDR indicated a significantly higher expression than those with simple PDR. IL-6 and tumour necrosis factor alpha in eyes with exacerbated PVR demonstrated a significantly higher expression than in those with simple PVR. However, there was no difference in SOF osmotic pressure between group of each disease. These studies indicate that disease-specific SOF is a significant reflection of disease status.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28572674 PMCID: PMC5454016 DOI: 10.1038/s41598-017-03124-x
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Patients’ characteristics.
| No. of patients (male) | Age | Duration of SO tamponade (months) | |
|---|---|---|---|
| RRD | 15 (13) | 55.4 ± 19.9 | 4.1 ± 2.1 |
| PDR | 17 (12) | 47.0 ± 12.0 | 4.5 ± 2.0 |
| PVR | 14 (10) | 50.6 ± 25.3 | 4.0 ± 2.1 |
| MHRD | 4 (1) | 55.4 ± 19.9 | 7.0 ± 2.3 |
RRD: Rhegmatogenous retinal detachment, PDR: Proliferative diabetic retinopathy, PVR: Proliferative vitreoretinopathy, MHRD: Macular hole-associated retinal detachment.
Figure 1Method for sub-silicone oil fluid (SOF) extraction. (a) Setting up an SOF extraction kit. (b) Once the surgeon places the tip of the blunt needle above the optic nerve the assistant pulls back the plunger of the syringe. The white dotted line indicates the border between the fluid and silicone oil.
Cytokine levels in SOF.
| Number of Samples | RRD | PDR | PVR | MHRD | |
|---|---|---|---|---|---|
| 15 | 17 | 14 | 4 | ||
| FGF-2 | (pg/mL) | 26.1 ± 22.9 | 37.4 ± 54.4 | 35.4 ± 30.5 | 11.5 ± 10.8 |
| IFNγ | (pg/mL) | 0 ± 0 | 2.3 ± 9.6 | 1.2 ± 3.0 | 0 ± 0 |
| IL-10 | (pg/mL) | 2.1 ± 4.0 | 6.8 ± 7.1 | 12.2 ± 9.9 | 2.4 ± 3.2 |
| IL-12p40 | (pg/mL) | 2.8 ± 5.0 | 7.7 ± 9.8 | 14.2 ± 17.6 | 1.7 ± 3.3 |
| IL-1β | (pg/mL) | 0 ± 0 | 1.5 ± 4.4 | 0 ± 0 | 0 ± 0 |
| IL-6 | (pg/mL) | 95.3 ± 133.6 | 317.9 ± 524.5 | 440.2 ± 701.4 | 31.7 ± 34.8 |
| IL-8 | (pg/mL) | 78.1 ± 65.1 | 79.4 ± 97.5 | 82.7 ± 40.7 | 30.9 ± 15.5 |
| MCP-1 | (pg/mL) | 6044.6 ± 2734.6 | 6670.5 ± 3251.1 | 12042.8 ± 7795.1 | 3582.5 ± 1764.2 |
| TNFα | (pg/mL) | 0.8 ± 2.2 | 0.9 ± 2.1 | 1.0 ± 2.5 | 1.3 ± 1.7 |
| VEGF | (pg/mL) | 32.0 ± 64.9 | 126.3 ± 197.3 | 156.6 ± 139.8 | 29.7 ± 23.6 |
| TGFβ1 | (pg/mL) | 105.7 ± 82.8 | 143.2 ± 125.4 | 215.6 ± 123.4 | 83.1 ± 31.2 |
RRD: Rhegtamogenous retinal detachment, PDR: Proliferative diabetic retinopathy, PVR: Proliferative vitreoretinopathy, MHRD: Macular hole-associated retinal detachment.
Figure 2Comparison of cytokine levels of sub-silicone oil fluid (SOF) and disease. The IL-10, IL-12p40, IL-6 and VEGF in SOF from eyes in patients with proliferative vitreoretinopathy (PVR) were significantly higher than those with rhegmatogenous retinal detachment (RRD). The monocyte chemoattractive protein-1 (MCP-1) in the SOF from eyes with PVR was significantly higher than those with macular hole-associated retinal detachment (MHRD).
Correlation between the amount of SOF and cytokine levels.
|
|
| |
|---|---|---|
| FGF-2 | −0.2004 | 0.1674 |
| IFNγ | −0.2958 | 0.0391 |
| IL-10 | −0.0729 | 0.6184 |
| IL-12p40 | −0.2311 | 0.1101 |
| IL-1β | −0.1301 | 0.3730 |
| IL-6 | −0.1635 | 0.2616 |
| IL-8 | 0.2562 | 0.0756 |
| MCP-1 | −0.0771 | 0.5987 |
| TNFα | 0.2933 | 0.0408 |
| VEGF | −0.2580 | 0.0735 |
| TGFβ1 | 0.0580 | 0.7020 |
Surgical procedures of PDR and PVR.
| Time of surgery (minutes) | Endolaser photocoagulation (shots) | Membrane remove (+/−) | Encircling (+/−) | Retinotomy (+/−) | |||
|---|---|---|---|---|---|---|---|
| 1st surgery | 2nd surgery | ||||||
| PDR | Simple | 92.8 ± 49.9 | 32.9 ± 10.6 | 1493.9 ± 935.0 | 10/0 | 0/10 | 0/10 |
| Exacerbated | 101.3 ± 31.1 | 73.1 ± 34.2 | 1715.0 ± 517.9 | 7/0 | 2/5 | 1/6 | |
|
| 0.46 | 0.0062 | 0.84 | ||||
| PVR | Simple | 116.0 ± 52.9 | 64.7 ± 33.9 | 1480.0 ± 588.7 | 6/0 | 0/6 | 0/6 |
| Exacerbated | 202.6 ± 97.7 | 89.6 ± 100.0 | 1113.5 ± 683.4 | 8/0 | 1/7 | 1/7 | |
|
| 0.071 | 0.014 | 0.16 | ||||
PDR: Proliferative diabetic retinopathy, PVR: Proliferative vitreoretinopathy.
Cytokine levels in SOF.
| Number of Samples | Simple PDR | Exacerbated PDR | Simple PVR | Exacerbated PVR | |
|---|---|---|---|---|---|
| 10 | 7 | 6 | 8 | ||
| FGF-2 | (pg/mL) | 27.8 ± 58.5 | 51.1 ± 48.3 | 17.8 ± 9.5 | 48.6 ± 34.6 |
| IFNγ | (pg/mL) | 0 ± 0 | 5.6 ± 14.9 | 0 ± 0 | 2.1 ± 3.8 |
| IL-10 | (pg/mL) | 2.8 ± 3.9 | 12.5 ± 6.8 | 7.5 ± 8.1 | 15.7 ± 10.1 |
| IL-12p40 | (pg/mL) | 2.1 ± 4.6 | 15.6 ± 9.8 | 7.2 ± 4.7 | 19.6 ± 22.0 |
| IL-1β | (pg/mL) | 1.4 ± 4.3 | 1.8 ± 4.7 | 0 ± 0 | 0 ± 0 |
| IL-6 | (pg/mL) | 213.6 ± 423.5 | 467.0 ± 648.5 | 125.3 ± 72.6 | 676.3 ± 872.4 |
| IL-8 | (pg/mL) | 44.8 ± 28.0 | 128.7 ± 139.1 | 88.2 ± 54.8 | 78.5 ± 29.9 |
| MCP-1 | (pg/mL) | 5308.8 ± 2634.9 | 8615.7 ± 3204.1 | 8339.8 ± 3143.2 | 14820.0 ± 9231.6 |
| TNFα | (pg/mL) | 0.3 ± 1.0 | 1.8 ± 3.0 | 2.4 ± 3.5 | 0 ± 0 |
| VEGF | (pg/mL) | 52.1 ± 61.6 | 232.3 ± 275.3 | 87.4 ± 83.2 | 208.5 ± 275.3 |
| TGFβ1 | (pg/mL) | 86.6 ± 99.9 | 224.2 ± 118.2 | 192.6 ± 135.3 | 225.3 ± 119.2 |
PDR: Proliferative diabetic retinopathy, PVR: Proliferative vitreoretinopathy.
Figure 3Difference in cytokine levels dependent on disease severity. The FGF-2, IL-10, IL-12p40, IL-8, VEGF and TGFβ1 levels in eyes with exacerbated PDR showed a significantly higher expression than those with simple PDR. The IL-6 and TNFα in eyes with exacerbated PVR showed significantly higher expression than those with simple PVR.
Changes in cytokine levels from the vitreous fluid to SOF.
| Number of Samples | RRD | Simple PDR | Exacerbated PDR | MHRD | |
|---|---|---|---|---|---|
| 4 | 3 | 4 | 2 | ||
| FGF-2 | (pg/mL) | 14.0 ± 23.7 | 40.4 ± 135.1 | 14.9 ± 8.9 | −145.8 ± 134.1 |
| IFNγ | (pg/mL) | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| IL-10 | (pg/mL) | −0.1 ± 0.6 | −1.6 ± 2.7 | 2.9 ± 3.8 | 1.0 ± 1.1 |
| IL-12p40 | (pg/mL) | −1.2 ± 1.4 | 4.5 ± 7.8 | 3.4 ± 1.9 | 0.1 ± 0.2 |
| IL-1β | (pg/mL) | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| IL-6 | (pg/mL) | −41.3 ± 64.5 | 304.8 ± 921.0 | 270.1 ± 594.6 | −5.6 ± 8.8 |
| IL-8 | (pg/mL) | −5.0 ± 22.2 | −36.9 ± 61.5 | 17.9 ± 168.1 | 8.3 ± 11.5 |
| MCP-1 | (pg/mL) | −1713.5 ± 1541.9 | 388.7 ± 3655.0 | −285.5 ± 1884.4 | 4.5 ± 529.6 |
| TNFα | (pg/mL) | −0.1 ± 0.1 | 0 ± 0 | −0.4 ± 3.1 | 2.6 ± 1.4 |
| VEGF | (pg/mL) | −110.1 ± 85.1 | −366.7 ± 600.4 | 54.6 ± 54.2 | −6.7 ± 12.3 |
| TGFβ1 | (pg/mL) | −5.1 ± 35.9 | −203.5 ± 54.9 | −117.8 ± 193.1 | 50.2 ± 77.8 |
RRD: Rhegmatogenous retinal detachment, PDR: Proliferative diabetic retinopathy, MHRD: Macular hole-associated retinal detachment.
Figure 4Changes in the osmotic pressure of vitreous fluid and sub-silicone oil fluid (SOF) from the same eyes. (a) The average SOF osmotic pressures from RRD, PVR, PVR, and MHRD. There were no significant difference between four groups. (b) The X-axis indicates the duration of SOF inside the eye and the Y-axis indicates the osmotic pressure. Note that the osmotic pressures in the vitreous fluid and SOF were not altered regardless of the disease or SOF duration. RRD: Rhegmatogenous retinal detachment, PDR: Proliferative diabetic retinopathy, MHRD: Macular hole-associated retinal detachment.
Osmotic pressures (mmol/kg) of the vitreous fluid and SOF from the same patients.
| Number of samples | Vitreous | SOF | |
|---|---|---|---|
| RRD | 4 | 284.0 ± 7.4 | 281.8 ± 6.9 |
| Simple PDR | 3 | 291.0 ± 1.0 | 287.7 ± 7.5 |
| Exacerbated PDR | 3 | 298.0 ± 11.3 | 290.7 ± 7.6 |
| MHRD | 2 | 289.0 ± 0.0 | 288.0 ± 4.2 |
RRD: Rhegmatogenous retinal detachment, PDR: Proliferative diabetic retinopathy, MHRD: Macular hole-associated retinal detachment.